1. Home
  2. VRAX vs LICN Comparison

VRAX vs LICN Comparison

Compare VRAX & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • LICN
  • Stock Information
  • Founded
  • VRAX 2013
  • LICN 2004
  • Country
  • VRAX United Kingdom
  • LICN China
  • Employees
  • VRAX N/A
  • LICN N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • LICN
  • Sector
  • VRAX Health Care
  • LICN
  • Exchange
  • VRAX Nasdaq
  • LICN Nasdaq
  • Market Cap
  • VRAX 4.4M
  • LICN 3.8M
  • IPO Year
  • VRAX 2022
  • LICN 2023
  • Fundamental
  • Price
  • VRAX $0.60
  • LICN $5.01
  • Analyst Decision
  • VRAX Strong Buy
  • LICN
  • Analyst Count
  • VRAX 1
  • LICN 0
  • Target Price
  • VRAX $3.00
  • LICN N/A
  • AVG Volume (30 Days)
  • VRAX 1.4M
  • LICN 84.8K
  • Earning Date
  • VRAX 01-01-0001
  • LICN 01-01-0001
  • Dividend Yield
  • VRAX N/A
  • LICN N/A
  • EPS Growth
  • VRAX N/A
  • LICN N/A
  • EPS
  • VRAX N/A
  • LICN N/A
  • Revenue
  • VRAX $6,331.00
  • LICN $41,477,000.00
  • Revenue This Year
  • VRAX $217,274.83
  • LICN N/A
  • Revenue Next Year
  • VRAX N/A
  • LICN N/A
  • P/E Ratio
  • VRAX N/A
  • LICN N/A
  • Revenue Growth
  • VRAX N/A
  • LICN 4.32
  • 52 Week Low
  • VRAX $0.52
  • LICN $2.60
  • 52 Week High
  • VRAX $3.62
  • LICN $462.00
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 36.69
  • LICN 57.69
  • Support Level
  • VRAX $0.54
  • LICN $4.16
  • Resistance Level
  • VRAX $0.59
  • LICN $5.76
  • Average True Range (ATR)
  • VRAX 0.06
  • LICN 0.47
  • MACD
  • VRAX 0.00
  • LICN 0.05
  • Stochastic Oscillator
  • VRAX 29.92
  • LICN 53.13

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: